Abviro Llc
CAGE Code: 75YF3
NCAGE Code: 75YF3
Status: Active
Type: Commercial Supplier
Summary
Abviro Llc is an Active Commercial Supplier with the Cage Code 75YF3.
Address
4800 Hampden Ln Ste 200
Bethesda MD 20814-2934
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Gross Engineering Co Inc Audiodontics Incorporated Health Trends Ervin And Associates Inc Institute For Family-Centered Care, Applications Valley Inc Bidsdelle Mary Beth Ltd Collins Computer Consulting Inc Informix Federal Div Privacy Times Inc. Alban Institute Inc Thieblot Aircraft Co Inc Travel Books And Language Center Inc Capital Office Systems, Inc. U S Dept Of Health And Human Ecoformic, Inc. Multigen Inc Business Objects Inc Quantegy Inc Barkley W Emmett
Frequently Asked Questions (FAQ) for CAGE 75YF3
- What is CAGE Code 75YF3?
- 75YF3 is the unique identifier used by NATO Organizations to reference the physical entity known as Abviro Llc located at 4800 Hampden Ln Ste 200, Bethesda MD 20814-2934, United States.
- Who is CAGE Code 75YF3?
- 75YF3 refers to Abviro Llc located at 4800 Hampden Ln Ste 200, Bethesda MD 20814-2934, United States.
- Where is CAGE Code 75YF3 Located?
- CAGE Code 75YF3 is located in Bethesda, MD, USA.
Contracting History for CAGE 75YF3 Most Recent 25 Records
- 75N93023C00055
- To Conduct A Phase 2 Dengue Human Challenge Clinical Trial Of Abviro Anti-Dengue Monoclonal Antibody (Mab) Av-1.
- 12 Dec 2023
- To Conduct A Phase 2 Dengue Human Challenge Clinical Trial Of Abviro Anti-Dengue Monoclonal Antibody (Mab) Av-1.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,752,967.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00055
- To Conduct A Phase 2 Dengue Human Challenge Clinical Trial Of Abviro Anti-Dengue Monoclonal Antibody (Mab) Av-1.
- 21 Sep 2023
- To Conduct A Phase 2 Dengue Human Challenge Clinical Trial Of Abviro Anti-Dengue Monoclonal Antibody (Mab) Av-1.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,752,967.00
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 17 Mar 2023
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,440,801.00
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 28 Sep 2023
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,438,889.31
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 23 Jun 2022
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,554,056.00
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 23 Jan 2023
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,440,801.00
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 9 Dec 2021
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,554,056.00
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 27 Sep 2022
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,431,751.73
- Department Of Health And Human Services (Hhs)
- HHSN272201600028C
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- 7 Jun 2021
- The Purpose Of This Contract Is To Develop A Monoclonal Antibody (Mab) Av-1 As A Safe Injectable Therapeutic.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $26,953,276.00
- Department Of Health And Human Services (Hhs)